NYSE:MTD (USA) Also trade in: Germany Mexico UK

Mettler-Toledo International Inc

$ 716.5 0.32 (0.04%)
Volume: 211,156 Avg Vol (1m): 143,654
Market Cap $: 17.77 Bil Enterprise Value $: 18.71 Bil
P/E (TTM): 34.49 P/B: 32.28
Earnings Power Value 182.61
Net Current Asset Value -43.68
Tangible Book -7.42
Projected FCF 206.78
Median P/S Value 353.29
Graham Number 0
Peter Lynch Value 279.36
DCF (FCF Based) 354.14
DCF (Earnings Based) 377.56
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.12
Cash-To-Debt ranked lower than
70.50% of 261 companies
in the Diagnostics & Research industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
MTD: 0.12
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.04, Med: 0.19, Max: 0.72
Current: 0.12
0.04
0.72
Equity-to-Asset 0.21
Equity-to-Asset ranked lower than
74.48% of 239 companies
in the Diagnostics & Research industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
MTD: 0.21
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.05, Med: 0.35, Max: 0.5
Current: 0.21
0.05
0.5
Debt-to-Equity 1.89
Debt-to-Equity ranked lower than
82.32% of 164 companies
in the Diagnostics & Research industry.
Industry Max: 22.86, Med: 0.36, Min: 0.01
MTD: 1.89
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.28, Med: 0.77, Max: 15.62
Current: 1.89
0.28
15.62
Debt-to-EBITDA 1.36
Debt-to-EBITDA ranked higher than
61.21% of 116 companies
in the Diagnostics & Research industry.
Industry Max: 77.72, Med: 1.77, Min: 0.03
MTD: 1.36
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: 0.85, Med: 1.13, Max: 1.83
Current: 1.36
0.85
1.83
Interest Coverage 19.60
Interest Coverage ranked lower than
50.92% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 15605.52, Med: 76.01, Min: 0.54
MTD: 19.6
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 11.25, Med: 18.6, Max: 19.79
Current: 19.6
11.25
19.79
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 9.40
DISTRESS
GREY
SAFE
Beneish M-Score -2.57
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 38.28%
WACC 10.81%

Profitability & Growth : 9/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 23.38
Operating Margin ranked higher than
90.08% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
MTD: 23.38
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 16.35, Med: 19.04, Max: 23.38
Current: 23.38
16.35
23.38
Net Margin % 17.98
Net Margin ranked higher than
82.99% of 241 companies
in the Diagnostics & Research industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
MTD: 17.98
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: 9.98, Med: 13.24, Max: 17.98
Current: 17.98
9.98
17.98
ROE % 95.64
ROE ranked higher than
99.17% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
MTD: 95.64
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: 28.42, Med: 38.53, Max: 95.64
Current: 95.64
28.42
95.64
ROA % 20.61
ROA ranked higher than
93.13% of 262 companies
in the Diagnostics & Research industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
MTD: 20.61
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: 10.2, Med: 15.3, Max: 20.61
Current: 20.61
10.2
20.61
ROC (Joel Greenblatt) % 77.82
ROC (Joel Greenblatt) ranked higher than
90.73% of 259 companies
in the Diagnostics & Research industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
MTD: 77.82
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 53.27, Med: 65.26, Max: 78.14
Current: 77.82
53.27
78.14
3-Year Total Revenue Growth Rate 7.00
3-Year Revenue Growth Rate ranked higher than
63.74% of 182 companies
in the Diagnostics & Research industry.
Industry Max: 371, Med: 4.8, Min: -100
MTD: 10.4
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -2.2, Med: 7.1, Max: 18
Current: 10.4
-2.2
18
3-Year Total EBITDA Growth Rate 11.60
3-Year EBITDA Growth Rate ranked higher than
62.36% of 178 companies
in the Diagnostics & Research industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
MTD: 15.1
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 2.7, Med: 11.2, Max: 20.7
Current: 15.1
2.7
20.7
3-Year EPS w/o NRI Growth Rate 16.80
3-Year EPS w/o NRI Growth Rate ranked lower than
55.83% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 138.7, Med: 10.1, Min: -301
MTD: 16.8
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 12.6, Max: 32
Current: 16.8
0
32

» MTD's 30-Y Financials

Financials (Next Earnings Date: 2019-07-26)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:MTD

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 621511    SIC : 8071
Compare NAS:IDXX NYSE:LH SHSE:603259 NYSE:WAT XSWX:LONN NYSE:DGX NAS:EXAS NYSE:A TSE:6869 XTER:SRT3 NAS:DXCM NYSE:PKI NYSE:IQV XPAR:BIM NYSE:BIO NYSE:QGEN XPAR:ERF NAS:ICLR NYSE:CRL NAS:PRAH
Traded in other countries MTO.Germany 0K10.UK
Address 1900 Polaris Parkway, Columbus, OH, USA, 43240
Mettler-Toledo supplies weighing and precision instruments to customers in the life sciences (50% of sales), industrial (43%), and food retail industries. Its products include laboratory and retail scales, pipettes, pH meters, thermal analysis equipment, titrators, metal detectors, and X-ray analyzers. Mettler leads the market for weighing instrumentation and controls more than 50% of the market for lab balances.

Ratios

Current vs industry vs history
PE Ratio (TTM) 34.49
PE Ratio ranked lower than
81.42% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35, Min: 0.33
MTD: 34.49
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 8.21, Med: 23.98, Max: 48.62
Current: 34.49
8.21
48.62
Forward PE Ratio 31.55
Forward P/E ranked lower than
70.00% of 40 companies
in the Diagnostics & Research industry.
Industry Max: 78.74, Med: 9999, Min: 11.64
MTD: 31.55
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 34.49
PE without NRI ranked lower than
78.76% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35.56, Min: 0.34
MTD: 34.49
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 8.21, Med: 23.98, Max: 48.62
Current: 34.49
8.21
48.62
Price-to-Owner-Earnings 35.69
Price-to-Owner-Earnings ranked lower than
72.37% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 1523.53, Med: 36.75, Min: 4.91
MTD: 35.69
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 7.47, Med: 24.99, Max: 42.16
Current: 35.69
7.47
42.16
PB Ratio 32.28
PB Ratio ranked lower than
77.96% of 245 companies
in the Diagnostics & Research industry.
Industry Max: 270, Med: 4.02, Min: 0.15
MTD: 32.28
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 3.04, Med: 8.01, Max: 34.35
Current: 32.28
3.04
34.35
PS Ratio 6.21
PS Ratio ranked lower than
57.83% of 230 companies
in the Diagnostics & Research industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
MTD: 6.21
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.85, Med: 3.06, Max: 6.77
Current: 6.21
0.85
6.77
Price-to-Free-Cash-Flow 40.60
Price-to-Free-Cash-Flow ranked lower than
61.25% of 80 companies
in the Diagnostics & Research industry.
Industry Max: 1356.19, Med: 29.22, Min: 0.35
MTD: 40.6
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 8.88, Med: 28.1, Max: 51.91
Current: 40.6
8.88
51.91
Price-to-Operating-Cash-Flow 31.24
Price-to-Operating-Cash-Flow ranked lower than
67.01% of 97 companies
in the Diagnostics & Research industry.
Industry Max: 1739.7, Med: 19.94, Min: 0.35
MTD: 31.24
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 6.52, Med: 20.95, Max: 35.62
Current: 31.24
6.52
35.62
EV-to-EBIT 26.88
EV-to-EBIT ranked lower than
62.71% of 118 companies
in the Diagnostics & Research industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
MTD: 26.88
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: 7, Med: 17.8, Max: 31.6
Current: 26.88
7
31.6
EV-to-EBITDA 23.94
EV-to-EBITDA ranked lower than
67.42% of 132 companies
in the Diagnostics & Research industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
MTD: 23.94
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: 6.1, Med: 15.7, Max: 28.1
Current: 23.94
6.1
28.1
EV-to-Revenue 6.34
EV-to-Revenue ranked lower than
57.44% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
MTD: 6.34
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 1, Med: 3.2, Max: 7.1
Current: 6.34
1
7.1
PEG Ratio 2.57
PEG Ratio ranked lower than
85.42% of 48 companies
in the Diagnostics & Research industry.
Industry Max: 128.13, Med: 3.26, Min: 0.32
MTD: 2.57
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 0.42, Med: 1.74, Max: 3.92
Current: 2.57
0.42
3.92
Shiller PE Ratio 58.00
Shiller PE Ratio ranked lower than
74.36% of 39 companies
in the Diagnostics & Research industry.
Industry Max: 459.08, Med: 52.49, Min: 10.19
MTD: 58
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 14.97, Med: 38.94, Max: 67.34
Current: 58
14.97
67.34
Current Ratio 1.37
Current Ratio ranked lower than
63.20% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
MTD: 1.37
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.83, Med: 1.51, Max: 2.27
Current: 1.37
0.83
2.27
Quick Ratio 0.97
Quick Ratio ranked lower than
59.60% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
MTD: 0.97
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.55, Med: 1.09, Max: 1.84
Current: 0.97
0.55
1.84
Days Inventory 79.98
Days Inventory ranked higher than
79.41% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 917.88, Med: 79.76, Min: 0.37
MTD: 79.98
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 67.18, Med: 74.01, Max: 79.98
Current: 79.98
67.18
79.98
Days Sales Outstanding 60.45
Days Sales Outstanding ranked lower than
51.47% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 521.64, Med: 67.51, Min: 1
MTD: 60.45
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 60.45, Med: 66.9, Max: 71.61
Current: 60.45
60.45
71.61
Days Payable 50.73
Days Payable ranked higher than
58.29% of 187 companies
in the Diagnostics & Research industry.
Industry Max: 981.81, Med: 63.34, Min: 1
MTD: 50.73
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 44.85, Med: 49.84, Max: 57.36
Current: 50.73
44.85
57.36

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate 2.70
3-Year Share Buyback Rate ranked higher than
98.33% of 180 companies
in the Diagnostics & Research industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
MTD: 2.7
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -4.8, Med: 3.1, Max: 6.7
Current: 2.7
-4.8
6.7

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 3.47
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
62.67% of 75 companies
in the Diagnostics & Research industry.
Industry Max: 449, Med: 2.41, Min: 0.47
MTD: 3.47
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.66, Med: 1.76, Max: 3.98
Current: 3.47
0.66
3.98
Price-to-DCF (Earnings Based) 1.90
Price-to-Intrinsic-Value-DCF (Earnings Based) ranked lower than
76.47% of 17 companies
in the Diagnostics & Research industry.
Industry Max: 6.59, Med: 1.86, Min: 0.72
MTD: 1.9
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
Price-to-Intrinsic-Value-DCF (Earnings Based) range over the past 10 years
Min: 0.36, Med: 1.04, Max: 2.49
Current: 1.9
0.36
2.49
Price-to-Median-PS-Value 2.03
Price-to-Median-PS-Value ranked lower than
74.09% of 193 companies
in the Diagnostics & Research industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
MTD: 2.03
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.3, Med: 0.68, Max: 2.05
Current: 2.03
0.3
2.05
Price-to-Peter-Lynch-Fair-Value 2.56
Price-to-Peter-Lynch-Fair-Value ranked lower than
96.67% of 30 companies
in the Diagnostics & Research industry.
Industry Max: 15.31, Med: 2.01, Min: 0.83
MTD: 2.56
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.46, Med: 1.81, Max: 4.42
Current: 2.56
0.46
4.42
Earnings Yield (Joel Greenblatt) % 3.71
Earnings Yield (Greenblatt) ranked higher than
72.08% of 265 companies
in the Diagnostics & Research industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
MTD: 3.71
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: 3.2, Med: 5.6, Max: 14.3
Current: 3.71
3.2
14.3
Forward Rate of Return (Yacktman) % 15.33
Forward Rate of Return ranked higher than
58.57% of 70 companies
in the Diagnostics & Research industry.
Industry Max: 7802.99, Med: 8.45, Min: -35.9
MTD: 15.33
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: 13.5, Med: 15.9, Max: 27.6
Current: 15.33
13.5
27.6

More Statistics

Revenue (TTM) (Mil) $ 2,954.22
EPS (TTM) $ 20.77
Beta 1.48
Volatility % 28.05
52-Week Range $ 500.74 - 762.9
Shares Outstanding (Mil) 33.85

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy Y
Higher Gross Margin yoy N
Higher Asset Turnover yoy N